Maraviroc: A Coreceptor CCR5 Antagonist for Management of HIV Infection

Raymond Yost; Timothy R. Pasquale; Eric G. Sahloff


Am J Health Syst Pharm. 2009;66(8):715-726. 

In This Article


Maraviroc is a small-molecule CCR5-ligand and an analogue of UK-107,453, a potent imidazopyridine ligand-efficient lead compound.[3] In in vitro studies, maraviroc inhibited CCR5 signaling and chemokine-dependent stimulation, had no effect on intracellular calcium concentrations, and did not lead to CCR5 internalization. Based on these findings, maraviroc was determined to have no agonistic activity and is an antagonist, either functional or inverse, of the CCR5 receptor.[3]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: